AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to

Brief description of study

The purpose of the study is to investigates how well nivolumab when given together with blinatumomab work compared to blinatumomab alone in treating patients with CD19+ B-cell acute lymphoblastic leukemia or Down syndrome that has come back (relapsed). Blinatumomab is an antibody, which is a protein that identifies and targets foreign substances in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs that kills the cancer cell. Nivolumab is a medicine that is used to boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.


Clinical Study Identifier: s20-01999
ClinicalTrials.gov Identifier: NCT04546399
Principal Investigator: Chana Glasser.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.